Weekly Top News – Psoriasis – September 28, 2020

September 28, 2020

Ilumya (tildrakizumab-asmn) / Sun Pharma, Almirall
Sun Pharma announces the launch of ILUMYA (tildrakizumab) for treatment of Plaque Psoriasis in Japan (Equitybulls) – Sep 23, 2020 – “Sun Pharmaceutical…today announced that its wholly-owned Japanese subsidiary has launched ILUMYA® Subcutaneous Injection 100 mg Syringe (Nonproprietary name: tildrakizumab (genetical recombination), ‘ILUMYA’) in Japan for the treatment of plaque psoriasis in adult patients who have an inadequate response to conventional therapies.”


bimekizumab (UCB4940) / UCB
UCB Achieves Important Regulatory Milestone for Bimekizumab (UCB Press Release) – Sep 22, 2020 – “UCB…today announced that the FDA and EMA have accepted the Biologics License Application (BLA) and Marketing Authorization Application (MAA), respectively, for bimekizumab for the treatment of adults with moderate to severe plaque psoriasis; This accepted submission is supported by a robust data package including three Phase 3 studies which demonstrate superiority of bimekizumab to placebo, Stelara[®] (ustekinumab) and Humira[®] (adalimumab) in achieving skin clearance at week 16.”


Cosentyx (secukinumab) / Novartis
Cosentyx: “Extension of indication to include the treatment of moderate to severe plaque psoriasis in children and adolescents from the age of 6 years who are candidates for systemic therapy [Plaque psoriasis]” (European Medicines Agency) – Sep 25, 2020 – CHMP Final Minutes of the meeting on 22-25 June 2020: “The Committee adopted a positive opinion by consensus together with the CHMP assessment report and translation timetable”


Tremfya (guselkumab) / J&J
Tremfya: “Addition of a new indication for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (DMARD) therapy [Psoriatic arthritis]” (European Medicines Agency) – Sep 25, 2020 – CHMP Final Minutes of the meeting on 22-25 June 2020: “The Committee adopted a 2nd request for supplementary information with a specific timetable”


piclidenoson (CF101) / Can-Fite, China Medical System
Can-Fite to Participate in Two BioPharma Partnering Conferences (Businesswire) – Sep 22, 2020 – “Can-Fite BioPharma Ltd….today announced the Company’s VP of Business Development, Dr. Sari Fishman, is participating in two conferences where she will conduct one-on-one meetings with pharmaceutical companies for potential distribution and partnerships for the Company’s drug candidates, Piclidenoson and Namodenoson. Both conferences include scheduled virtual partner meetings for Can-Fite, live sessions, and virtual networking….Additional trials are ongoing or expected to start in COVID-19 and liver cancer.”


Ilumya (tildrakizumab-asmn) / Sun Pharma, Almirall
Efficacy and Safety of Tildrakizumab in the Treatment of Scalp Psoriasi (clinicaltrials.gov) – Sep 22, 2020 – P3; N=214; Active, not recruiting; Sponsor: Sun Pharma Global FZE; Recruiting –> Active, not recruiting; Trial completion date: Aug 2022 –> Feb 2022; Trial primary completion date: Jun 2021 –> Jan 2021

No Comments

Post a Comment